comparemela.com

Latest Breaking News On - Healthcare royalty partners - Page 3 : comparemela.com

Tenapanor for Hyperphosphatemia Approved in Japan

Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty.

Ardelyx Says Japan Approves Tenapanor For Hyperphosphatemia

(RTTNews) - Biopharmaceutical company Ardelyx, Inc. (ARDX) announced Monday that its collaboration partner in Japan, Kyowa Kirin Co., Ltd., has re.

Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone (NASDAQ:RPRX)

Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone (NASDAQ:RPRX)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.